Poster Session 3-13 MDS: Clinical (4)

Sun. Oct 14, 2018 12:40 PM - 1:20 PM Poster1 (Osaka International Convention Center, 3F Event Hall)

Chair: Masao Hagihara (Department of Hematology, Eijn General Hosp.)

+Add all to schedule

[PS3-13-1] Secondary pulmonary alveolar proteinosis during azacitidine treatment in patient with MDS

Sawako Shiraiwa¹, Norisato Hashimoto¹, Tomoki Ueda¹, Yusuke Kondo², Yoko Ito², Gen Tazaki², Fumio Sakamaki², Haruyuki Ishii³, Kiyoshi Ando⁴, Kenji Yokoyama¹ (1.Hematology/Oncology, Tokai University Hachioji Hospital, Tokyo, Japan, 2.Respiratory, Tokai University Hachioji Hospital, 3.Kyorin University, 4.Hematology/Oncology, Tokai University)

[PS3-13-2] The prognostic value of peripheral blasts in patients with MDS treated with azacitidine

Takahiro Kamiya, Kota Mizuno, Kyoko Masuda, Masahiro Akimoto, Shinji Ogura, Chisako Ito, Yuriko Fujita, Yoshinobu Aisa, Tomonori Nakazato (Department of Hematology, Yokohama Municipal Citizen's Hospital)

[PS3-13-3] The alternating therapy of azacitidine and Ara-C may improve survival of AML/MDS

Kunio Hayashi¹, Hirokazu Ikegame² (1.Division of Hematology, Meiwa General Hospital, 2.Department of Hematology, Hyogo College of Medicine)

[PS3-13-4] A retrospective study evaluating early infectious complications during azacitidine treatment

Chisako Ito, Kyoko Masuda, Masahiro Akimoto, Takahiro Kamiya, Kota Mizuno, Shinji Ogura, Yuriko Fujita, Yoshinobu Aisa, Tomonori Nakazato (Department of Hematology, Yokohama Municipal Citizen's Hospital)

[PS3-13-5] Clinical significance of WT1 mRNA levels in the diagnosis and treatment of myelodysplastic syndrome

Michihiro Uchiyama (Department of Hematology, Suwa Red Cross Hospital, Nagano, Japan)

[PS3-13-6] Real-world data for high-risk myelodysplastic syndrome in southern Taiwan

Ming-Hui Lin¹, Hui-Hua Hsiao^1,2,3, Jeng-Shiun Du^1,4, Hui-Ching Wang^1,4, Yu-Fen Tsai^1,4, Yi-Chang Liu^1,2, Ta-Chih Liu^1,2,3 (1.Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Taiwan, Kaohsiung, Taiwan, 2.Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung city, Taiwan, 3.Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung city, Taiwan, 4.Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung city, Taiwan)

[PS3-13-7] Clinical result of darbepoietin alpha in low grade myelodysplastic syndrome (MDS)

Yoshinobu Seki, Ouki Nagano (Hematol., Uonuma, Niigata Univ., Niigata, Japan)

[PS3-13-8] Lenalidomide treatment for high risk MDS and AML with chromosome 5q deletion

Sayoko Ohkawara¹, Midori Goto¹, Toru Watanabe¹, Kenichi Akao¹, Makoto Hirosawa¹, Ai Kawahara¹, Noriaki Kitamura², Tsukasa Nakanishi¹, Takahiro Yamaguchi¹, Aya Tanaka¹, Takefumi Katsuragi³, Takehiro Higashi¹, Hiroaki Morimoto¹, Junichi Tsukada¹ (1.Department of Hematology,Hospital of University of Occupational and Environmental Health,Fukuoka,Japan, 2.Wakamatsu Hospital of University of Occupational and Environmental Health,Fukuoka,Japan, 3.Department of Hematology,Kitakyushu General Hospital,Fukuoka,Japan)

Session information

Poster Session 3-13 MDS: Clinical (4)